COVID-19 severity and vaccine breakthrough infections in idiopathic inflammatory myopathies, other systemic autoimmune and inflammatory diseases, and healthy controls: a multicenter cross-sectional study from the COVID-19 Vaccination in Autoimmune Diseases (COVAD) survey.
Hoff LS, Ravichandran N, Shinjo SK, Day J, Sen P, Junior JG, Lilleker JB, Joshi M, Agarwal V, Kardes S, Kim M, Milchert M, Makol A, Gheita T, Salim B, Velikova T, Gracia-Ramos AE, Parodis I, O'Callaghan AS, Nikiphorou E, Tan AL, Chatterjee T, Cavagna L, Saavedra MA, Ziade N, Knitza J, Kuwana M, Nune A, Distler O, Cansu DÜ, Traboco L, Wibowo SAK, Tehozol EAZ, Serrano JR, La Torre IG, Wincup C, Pauling JD, Chinoy H, Agarwal V, Aggarwal R, Gupta L; COVAD Study Group.
Hoff LS, et al. Among authors: gupta l.
Rheumatol Int. 2023 Jan;43(1):47-58. doi: 10.1007/s00296-022-05229-7. Epub 2022 Oct 22.
Rheumatol Int. 2023.
PMID: 36271958
Free PMC article.